OA11570A - 4-Benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists. - Google Patents

4-Benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists. Download PDF

Info

Publication number
OA11570A
OA11570A OA1200000347A OA1200000347A OA11570A OA 11570 A OA11570 A OA 11570A OA 1200000347 A OA1200000347 A OA 1200000347A OA 1200000347 A OA1200000347 A OA 1200000347A OA 11570 A OA11570 A OA 11570A
Authority
OA
OAPI
Prior art keywords
benzooxazol
piperidin
ethanesulfinyl
compound
benzyl
Prior art date
Application number
OA1200000347A
Other languages
English (en)
Inventor
Suzanne Ross Kesten
Nancy C Lan
Ravindra B Upasani
Jonathan L Wright
Original Assignee
Cocensys Inc
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocensys Inc, Warner Lambert Co filed Critical Cocensys Inc
Publication of OA11570A publication Critical patent/OA11570A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA1200000347A 1998-06-26 1999-06-25 4-Benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists. OA11570A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9091498P 1998-06-26 1998-06-26

Publications (1)

Publication Number Publication Date
OA11570A true OA11570A (en) 2004-07-01

Family

ID=22224939

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000347A OA11570A (en) 1998-06-26 1999-06-25 4-Benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists.

Country Status (28)

Country Link
US (1) US6284774B1 (ja)
EP (1) EP1089735B1 (ja)
JP (1) JP2002519322A (ja)
KR (1) KR20010053170A (ja)
CN (1) CN1304307A (ja)
AP (1) AP2000001949A0 (ja)
AT (1) ATE297207T1 (ja)
AU (1) AU769650B2 (ja)
BG (1) BG105082A (ja)
BR (1) BR9911575A (ja)
CA (1) CA2327888A1 (ja)
DE (1) DE69925730T2 (ja)
EA (1) EA200100058A1 (ja)
EE (1) EE200000778A (ja)
ES (1) ES2244201T3 (ja)
HU (1) HUP0102471A2 (ja)
ID (1) ID28005A (ja)
IL (1) IL138949A0 (ja)
IS (1) IS5667A (ja)
NO (1) NO20006482L (ja)
NZ (1) NZ508808A (ja)
OA (1) OA11570A (ja)
PE (1) PE20000728A1 (ja)
PL (1) PL345024A1 (ja)
SK (1) SK19512000A3 (ja)
TR (1) TR200003888T2 (ja)
WO (1) WO2000000197A1 (ja)
ZA (1) ZA200005848B (ja)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
UA73749C2 (en) * 1999-11-01 2005-09-15 Diarylenines
OA12253A (en) 2000-04-26 2006-05-11 Warner Lambert Co Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
BR0111279A (pt) * 2000-06-01 2003-11-04 Warner Lambert Co Derivados da ciclohexilamina como antagonistas para o receptor do nmda seletivo ao subtipo
ES2291329T3 (es) * 2000-07-18 2008-03-01 Dainippon Sumitomo Pharma Co., Ltd. Inhibidores de la recaptacion de serotonina.
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
WO2002068409A1 (en) 2001-02-23 2002-09-06 Merck & Co., Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
EP1436258A4 (en) * 2001-03-08 2005-03-23 Univ Emory ANTAGONISTS OF THE NMDA RECEPTOR DEPENDENT OF PH
AU2002338334B8 (en) 2001-04-03 2008-09-18 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists
CA2381630A1 (en) * 2001-04-23 2002-10-23 Leonard Theodore Meltzer Method for preventing dyskinesias
EP1409477B1 (en) 2001-07-24 2008-09-17 Richter Gedeon NYRT Piperidine derivatives as nmda receptor antagonists
CA2459161A1 (en) 2001-08-31 2003-03-13 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain
AU2002360600B2 (en) * 2001-12-11 2007-11-29 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
EP1845968A2 (en) 2004-11-24 2007-10-24 Neuromolecular Pharmaceuticals, Inc Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US20060142186A1 (en) * 2004-12-23 2006-06-29 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of alzheimer's disease
DE602006009670D1 (de) * 2005-08-15 2009-11-19 Univ Virginia Neurorestauration mit r(+) pramipexol
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
CA2652251A1 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods for using the same
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
AU2008224844B2 (en) 2007-03-14 2012-08-09 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
EP2170334B1 (en) * 2007-06-29 2021-03-17 Emory University Nmda receptor antagonists for neuroprotection
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
TWI410420B (zh) * 2008-02-05 2013-10-01 Dainippon Sumitomo Pharma Co 苄基哌啶化合物
EP2273988B1 (en) 2008-04-18 2015-09-09 Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona L-dopa for treating age-related macular degeneration
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
HUP0900130A3 (en) 2009-03-03 2012-02-28 Richter Gedeon Nyrt Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
WO2011016468A1 (ja) 2009-08-04 2011-02-10 大日本住友製薬株式会社 ベンジルピペリジン化合物
EP2461673A4 (en) 2009-08-05 2013-08-07 Intra Cellular Therapies Inc NEW REGULATOR PROTEINS AND HEMMER
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
CA2994873A1 (en) 2009-12-02 2011-06-09 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN102791704B (zh) 2010-03-10 2015-11-25 前体生物药物股份公司 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
CA2851387A1 (en) 2011-11-22 2013-05-30 The Regents Of The University Of California Cysteamine and/or cystamine for treating ischemic injury
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
DK3019167T3 (da) 2013-07-12 2021-03-15 Knopp Biosciences Llc Behandling af forhøjede niveauer af eosinophiler og/eller basophiler
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
WO2015023790A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
WO2016100823A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
BR112020003375A2 (pt) 2017-08-24 2020-08-25 Adamas Pharma, Llc composições de amantadina, preparações das mesmas, e métodos de uso
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
EP3958973A4 (en) * 2019-04-26 2023-06-07 Cytosolve, Inc. COMPOSITIONS TO IMPROVE BRAIN HEALTH AND MEMORY

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792187A (fr) * 1971-12-03 1973-03-30 Sumitomo Chemical Co Nouveaux derives d'alkylamines
DE2845537A1 (de) * 1978-10-19 1980-04-30 Bayer Ag Benzimidazolylcarbamidsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
EP0488959A3 (en) 1990-11-28 1992-08-05 Sandoz Ltd. New uses of competitive nmda receptor antagonists
JPH05194505A (ja) * 1991-08-09 1993-08-03 Yoshitomi Pharmaceut Ind Ltd チオフェン化合物
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
JP2959615B2 (ja) * 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
DK0709384T3 (da) 1994-10-31 1999-08-23 Merck Patent Gmbh Benzylpiperidinderivater med høj affinitet til aminosyrereceptorers bindingssteder
EP0825984A1 (en) * 1995-04-07 1998-03-04 Novo Nordisk A/S Novel method
ZA9610741B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
AU4376997A (en) * 1996-10-04 1998-05-05 Novo Nordisk A/S N-substituted azaheterocyclic compounds
DE19643790A1 (de) 1996-10-30 1998-05-07 Merck Patent Gmbh Benzoxazol-Derivat

Also Published As

Publication number Publication date
DE69925730D1 (de) 2005-07-14
EP1089735A4 (en) 2002-12-18
EA200100058A1 (ru) 2001-08-27
US6284774B1 (en) 2001-09-04
AU769650B2 (en) 2004-01-29
PL345024A1 (en) 2001-11-19
WO2000000197A1 (en) 2000-01-06
EE200000778A (et) 2002-04-15
NO20006482D0 (no) 2000-12-19
KR20010053170A (ko) 2001-06-25
AU4830399A (en) 2000-01-17
ES2244201T3 (es) 2005-12-01
PE20000728A1 (es) 2000-08-21
JP2002519322A (ja) 2002-07-02
AP2000001949A0 (en) 2000-12-31
IL138949A0 (en) 2001-11-25
DE69925730T2 (de) 2006-03-23
TR200003888T2 (tr) 2001-06-21
SK19512000A3 (sk) 2001-08-06
CA2327888A1 (en) 2000-01-06
CN1304307A (zh) 2001-07-18
NO20006482L (no) 2000-12-19
EP1089735A1 (en) 2001-04-11
EP1089735B1 (en) 2005-06-08
BR9911575A (pt) 2001-03-20
HUP0102471A2 (hu) 2002-05-29
ATE297207T1 (de) 2005-06-15
ID28005A (id) 2001-05-03
ZA200005848B (en) 2001-12-18
BG105082A (en) 2001-09-28
IS5667A (is) 2000-10-16
NZ508808A (en) 2002-12-20

Similar Documents

Publication Publication Date Title
OA11570A (en) 4-Benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists.
AU719430B2 (en) 4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists
EP0869792B1 (en) 4-substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
US6534525B1 (en) 2-substituted piperidine analogs and their use as subtype-selective NMDA receptor antagonists
US6534522B2 (en) Subtype-selective NMDA receptor ligands and the use thereof
MXPA00010169A (en) 4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists
CZ20004725A3 (cs) 4-Benzylpiperidinové alkylsulfoxidové heterocykly a jejich použití jako subtypověselektivních antagonistů NMDA receptorů
Baudy Agents for the treatment of neurodegenerative diseases: July-December 1996